NTX-301
Platinum-resistant/refractory advanced ovarian cancer, bladder cancer, and other solid tumors
Phase 1/2Active
Key Facts
Indication
Platinum-resistant/refractory advanced ovarian cancer, bladder cancer, and other solid tumors
Phase
Phase 1/2
Status
Active
Company
About Xennials Therapeutics
Xennials Therapeutics is a private, pre-revenue biotech leveraging a proprietary nanoparticle-based drug delivery platform to develop novel oncology therapeutics. Its lead asset, NTX-301 (a DNMT1 inhibitor), is in a Phase 1/2 study for various solid tumors, exploring monotherapy and combinations. The company emphasizes a strategy of coupling novel anti-cancer assets with its targeted delivery technology to address significant unmet needs in oncology treatment paradigms.
View full company profile